PARD Projected Dividend Yield
Poniard Pharmaceuticals Inc ( OTCBB : PARD )Poniard Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of cancer therapeutics. Co.'s primary product candidate is picoplatin, a platinum-based cancer therapy that is being researched to become a platform product for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications, including small cell lung, colorectal, prostate and ovarian cancers. Picoplatin is designed to treat solid tumors that are resistant to existing platinum-based cancer therapies. Co. holds a license granted from Genzyme Corporation for the development and commercial sale of picoplatin. 20 YEAR PERFORMANCE RESULTS |
PARD Dividend History Detail PARD Dividend News PARD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |